Back to Agenda
FDA Town Hall
Session Chair(s)
Amy Bertha
Executive Director, Regulatory Policy and Science, Bayer, United States
The FDA Town Hall provides a unique opportunity to hear directly from FDA leadership about key priorities. This year’s session will explore the evolving intersection of artificial intelligence (AI), real-world data (RWD), and real-world evidence (RWE), and how these elements are shaping drug and biologics development, regulatory expectations, and patient engagement.
Learning Objective : Discuss FDA Center priorities.
Speaker(s)
Marie Bradley, MPH
Senior Advisor, Real-World Evidence , Office of Medical Policy, CDER, FDA, United States
Panelist
Tamei Elliott, MS
Director, Global Scientific Content, DIA, United States
Panelist
Hussein Ezzeldin, PhD
Senior Public Health Advisor, FDA, United States
Panelist
Tala Fakhouri, PhD, MPH
Chief AI & Regulatory Strategy Officer, Parexel, United States
Panelist
Gabriel Innes, DVM, PhD
Assistant Director for Data Science and Artificial Intelligence, CDER, FDA, United States
Panelist
Shantanu Nundy, MD
Adjunct professor, courtesy appointment, Johns Hopkins Carey School of Business, United States
Panelist
Jeremy Walsh
Chief AI Officer, OC, FDA, United States
Panelist
Have an account?